Zai gets Asia-Pacific license to Entasis' antibiotic combinations

Zai Lab Ltd. (NASDAQ:ZLAB) received an exclusive license to develop and commercialize ETX2514/sulbactam from Entasis Therapeutics Inc. (Waltham, Mass.) in

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE